Logo

    c. diff

    Explore " c. diff" with insightful episodes like "What We Know About the Microbiome", "Specialist Spotlight: Gastroenterologist, Dr. Paul Feuerstadt talks on all things C. diff, the microbiota, and gut bacteria's link to overall health", "What is the Occurrence of Respiratory Viruses on School Desks?", "Encore: The Microbiome, C. Diff, and Clinical Trials During COVID-19" and "The Microbiome, C. Diff, and Clinical Trials During COVID-19" from podcasts like ""I AM BIO", "PV Roundup - Medical News Podcast", "AJIC Podcasts", "C. diff. Spores and More" and "C. diff. Spores and More"" and more!

    Episodes (7)

    What We Know About the Microbiome

    What We Know About the Microbiome

    The gut microbiome, which consists of trillions of bacteria, viruses, and fungi, plays a crucial role in our health. However, there is still much to learn about this complex ecosystem. On this episode we talk with experts who tell us where the science is—how much we know, and how much we don’t. Two companies, Bloom Science and Seres Therapeutics, are leveraging the microbiome to develop new therapeutics. The potential of the microbiome is vast, and further research and technological advancements will continue to unlock its benefits.

    Follow us on LinkedIn, X, Facebook and Instagram

    Visit us at https://www.bio.org/

    What is the Occurrence of Respiratory Viruses on School Desks?

    What is the Occurrence of Respiratory Viruses on School Desks?

    Today we have the pleasure to hear from Dr. Jordan Peccia as he discusses his study on the "Occurrence of Respiratory Viruses on School desks."  We also have a summary by Dr. Mohamed Yassin of the research from Dr. Danielle Durant -  "Can Patient-Reported Room Cleanliness Measures Predict Hospital-Acquired C. difficile Infection?" Today’s podcast is all about environmental cleanliness or that lack thereof and how it can affect our health. Stay tuned!

    The full articles can be found in the April 2021 edition of AJIC.

    This episode is brought to you by the American Journal of Infection Control (AJIC) and Infection Prevention Spotlight. 

    Encore: The Microbiome, C. Diff, and Clinical Trials During COVID-19

    Encore: The Microbiome, C. Diff, and Clinical Trials During COVID-19
    Join us with Guest; Mrs. Courtney Jones as we discuss we can cover the microbiome & C. diff (my area of knowledge), the importance of clinical trials in general, and how we as an industry are navigating the pandemic as other diseases don’t just “wait” for it to be over. Courtney will be discussing the human gut microbiome along with the C. diff. infection, recurrences, and major topics of both. Bring your tablet and prepare to take notes on these important topics.

    The Microbiome, C. Diff, and Clinical Trials During COVID-19

    The Microbiome, C. Diff, and Clinical Trials During COVID-19
    Join us with Guest; Mrs. Courtney Jones as we discuss we can cover the microbiome & C. diff (my area of knowledge), the importance of clinical trials in general, and how we as an industry are navigating the pandemic as other diseases don’t just “wait” for it to be over. Courtney will be discussing the human gut microbiome along with the C. diff. infection, recurrences, and major topics of both. Bring your tablet and prepare to take notes on these important topics.

    Superbuggin’

    Superbuggin’
    Incurable gonorrhea and the deadly hospital superbug C. diff offer a frightening window into the gathering public health menace of antibiotic resistance. If society doesn’t wake up and tackle the problem, we could be headed toward a calamity on the magnitude of climate change. Hosted by Jim Greenwood.

    New antimicrobials show promise in battle against superbug - Naked Scientists Special Editions 17.09.16

    New antimicrobials show promise in battle against superbug - Naked Scientists Special Editions 17.09.16
    C. diff - or Clostridium difficile - is a superbug that can cause major problems in hospitals. It leads to life-threatening diarrhoea and intestinal inflammation in patients who catch it, it spreads easily, and patients who do recover often relapse many times afterwards because the spectrum of so-called "good bacteria" in the bowel also goes off-kilter when you treat the infection. What's needed are highly-targeted antibiotics that can hit exclusively c. diff and not affect the good bacteria that we need to keep us healthy. Luckily, Sheffield University's Joe Kirk is on the case...
    Logo

    © 2024 Podcastworld. All rights reserved

    Stay up to date

    For any inquiries, please email us at hello@podcastworld.io